Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | MAPT | P10636 | 3/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.92 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.68 |
| ▸ | USP2 | O75604 | 5/20 | 0.68 |
| ▸ | PGR | P06401 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.68 |
| ▸ | MLNR | O43193 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | MMP1 | P03956 | 3/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobetasone Butyrate SCHEMBL11750078 | 0.96 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL29410388 | 0.96 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL448850 | 0.96 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL14339619 | 0.96 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL36599 | 0.96 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL11124627 | 0.96 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL29572705 | 0.96 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| SCHEMBL568167 | 0.93 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| SCHEMBL28099304 | 0.93 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| SCHEMBL11849414 | 0.91 | LMNA (0.77) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112566650-A | Heterodimeric proteins and uses thereof | 沙塔克实验室有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-111328284-A | Compositions and methods for maintaining and restoring a healthy intestinal barrier | 芬奇治疗公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-111328331-A | Compositions and methods for decolonizing antibiotic-resistant bacteria in the intestinal tract | 芬奇治疗公司 | 2020-06-23 | — | — | CN | disclosed |
| EP-1666473-B1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-8138335-B2 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-1486491-B1 | CARBOXYLIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20100029631-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7601712-B2 | Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7351705-B2 | Carboxylic acid compounds and a pharmaceutical agent comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20070004716-A1 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1666473-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1600440-A1 | INDOLE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1486491-A1 | CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| CN-1252003-A | Solvent system for enhancing permeation of pharmaceutical compounds | JOHNSON & JOHNSON CONSUMER (US) | 2000-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | PTGIS, IDO1, IDO2 | LMNA 4422/4885MAPT 965/4885SMN1; SMN2 3185/4885 |
| US-20100029631-A1 | CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | GPR17, CYSLTR1, KIT | LMNA 4266/4885MAPT 1750/4885SMN1; SMN2 3630/4885 |
| US-20070004716-A1 | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | GPR17, CYSLTR1, KIT | LMNA 4266/4885MAPT 1750/4885SMN1; SMN2 3630/4885 |
| US-20050222216-A1 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient | UACA, CPA3, HCAR1 | LMNA 4217/4885MAPT 1589/4885SMN1; SMN2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.